查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1133515

放射性藥物全球市場-2022-2029

Global Radiopharmaceuticals Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

放射性藥物市場的增長是由癌症和神經系統疾病等各種疾病的發病率上升、放射性藥物在疾病診斷和治療中的應用增加、人口老齡化加劇以及研發活動推動的。 .

放射性藥物的產品開發不斷增加，預計將推動市場增長。

癌症和心血管疾病等疾病的患病率上升預計將在預測期內提振市場。根據美國國家癌症研究所 2020 年 10 月的數據報告，研究人員目前正在設計和測試各種癌症的放射性藥物，包括肺癌、黑色素瘤、結腸癌和白血病。我們還重複使用櫓 Lu 177 等目標分子來攜帶更有效的放射性化合物和同位素。例如，前列腺癌一直是這種重新利用的早期試驗場。 PSMA 在前列腺細胞中含量豐富，其中大部分僅存在於前列腺細胞中。通過將與 PSMA 結合的分子與放射性化合物融合，它可用於通過 PET 掃描進行診斷成像。

此外，將放射性藥物與其他治療結合使用可能是促進其改善的一種方法。一些研究人員現在正在測試放射性藥物與放射增敏劑（使癌細胞更容易受到輻射的藥物）的組合。例如，在臨床試驗中，櫓 Lu177 dotatate 和放射增敏劑 Triapine 的組合可抑制細胞在放射損傷後產生 DNA 修復所需的化合物。

放射性藥物治療的缺點阻礙了市場增長

然而，放射性藥物治療的缺點包括輻射風險、非疾病特異性成像，因為這種治療通常需要注射到血液中、放射性廢物的處理以及治療成本高等等。這些因素都在抑制市場的增長。

COVID-19 影響分析

COVID-19 的出現對全球放射性藥物市場產生了相當大的影響。冠狀病毒 19 病 (COVID-19) 大流行無疑給全球醫療保健系統帶來了重大挑戰。輝瑞在一份聲明中表示，COVID-19 對癌症患者的最大影響之一是暫停手術和臨床試驗引起的恐懼。 2020 年 4 月，英國癌症研究委員會報告稱，全英國每週接受腸癌、乳腺癌和宮頸癌篩查的人數比大流行前減少了約 20 萬人，並且診斷出大量早期癌症。 .放療療程也明顯減少，2020 年 4 月減少近 20%，5 月減少 6.2%，6 月減少 11.6%，與 2019 年同月相比。

此外，即使在大流行期間，一些組織也在進行研究。例如，癌症研究所 (CRI) 報告了對在世界各地機構進行癌症臨床試驗的 36 名研究人員的調查結果。到 2022 年，情況正在從 COVID-19 中恢復，患者可以獲得適當的治療，從而導致全球放射性藥物治療的市場增長。

全球放射性藥物市場報告將提供對大約 65 多個市場數據表、65 多個數字和 200 多頁（大約）的訪問。

內容

第一章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因子
    • 驅動程序
      • 癌症和心血管疾病的高發率
      • 對傳染病措施的需求增加
    • 約束因素
      • 放射性藥物的半衰期短
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第7章放射性同位素

  • Tech99
  • F18
  • 碘 131
  • 櫓 177
  • 釔90
  • 鎵-68
  • 鎵-67
  • 銣 82
  • 碘 123
  • 碘 125
  • 銦 111
  • 其他

第 8 章. 按應用程序

  • 腫瘤學
  • 循環區
  • 腸胃科
  • 神經內分泌學
  • 神經內科
  • 神經內科
  • 其他

第九章來源

  • 迴旋加速器
  • 核反應堆

第 10 章，最終用戶

  • 醫院
  • 影像診斷中心
  • 門診手術中心
  • 癌症研究所

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 按治療類型劃分的基準

第 13 章公司簡介

  • Siemens AG
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Positron Corporation
  • Curium
  • GE Healthcare
  • Lantheus Holdings Inc.
  • Sotera Health LLC
  • Bayer AG
  • Eckert & Ziegler
  • Novartis AG
  • BWX Technologies Inc.

第 14 章全球放射性藥物市場-DataM

簡介目錄
Product Code: DMPH562

Market Overview

Radiopharmaceuticals Market size was valued at USD 6,242.80 million in 2021 and is estimated to reach a compound annual growth rate (CAGR) of 6.2% over the forecast period 2022 to 2029.

Radiopharmaceuticals contain radioactive substances used to diagnose or treat diseases, including cancer or cardiology. These are used for the diagnosis of abscess and infection, blood vessel diseases, bone diseases, colorectal disease and others.

Market Dynamics

The radiopharmaceuticals market growth is driven by the rise in prevalence of different diseases such as cancer, and neurological disorders, rising adoption of radiopharmaceuticals for diagnosis and treatment of diseases, increase in the geriatric population, and research and development activities.

The rising product development in radiopharmaceutical is expected to drive the market growth

The rising prevalence of diseases such as cancer and cardiovascular diseases is expected to boost the market over the forecast period. According to the National Cancer Institute October 2020 data report, researchers have recently designed and tested radiopharmaceuticals for various cancers as diverse as lung, melanoma, colorectal, and leukemia. Also, researchers have repurposed, such as Lutetium Lu 177, targeting molecules to carry more potent radioactive compounds, or isotopes, instead ones that could kill cancer cells instead of simply helping visualize them. For instance, prostate cancer has been an early testing ground for this repurposing. PSMA is found in large amounts and almost exclusively on prostate cells. Fusing a molecule that binds PSMA to a radioactive compound is used in PET scan imaging.

Moreover, using radiopharmaceuticals in combination with other therapies may be one way to drive that improvement. Some researchers are now testing radiopharmaceuticals combined with radiation sensitizers-drugs that make cancer cells even more vulnerable to radiation. For example, a clinical trial of lutetium Lu 177-dotatate combined with a radiation sensitizer called triapine, blocks cells from producing the compounds needed for DNA repair after radiation-induced damage.

The disadvantages of radiopharmaceuticals therapy will hamper the growth of the market

However, the disadvantages of radiopharmaceutical therapy include radiation risks, images that are not usually disease-specific, in this therapy typically requiring injection into the bloodstream, disposal of radioactivity waste and high cost of the treatment. These factors are restraining the market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global radiopharmaceuticals market. The coronavirus-19 disease (COVID-19) pandemic has undoubtedly posed significant challenges to healthcare systems globally. According to a statement by Pfizer, one of the greatest effects of COVID-19 on cancer patients is fear due to surgery and clinical trial disruptions. In addition, Cancer Research UK reported in April 2020 that a considerable number of early cancers would go undiagnosed, as there was a significant reduction in the number of people being screened for bowel, breast and cervical cancer across the UK, approximately 200,000 fewer per week than before the pandemic. There was also a significant decrease in radiotherapy treatment courses, nearly 20 % in April 2020, 6.2 % in May and 11.6 % in June, compared to the same months in 2019.

In addition, some organizations are conducting their studies even during a pandemic. For instance, the Cancer Research Institute (CRI) reported the results of a survey of 36 investigators conducting cancer clinical trials at institutions around the world. In 2022 situation is recovering from COVID-19, and the patient can access the proper treatments, leading to market growth of radiopharmaceutical therapy worldwide.

Segment Analysis

The oncology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The oncology segment is expected to boost the market throughout the forecast. The article was published in Future Oncology in June 2020; reported that, as per the WHO, worldwide cancer cases are predicted to increase around 60%, from 18.1 million in 2018 to 29.4 million by 2040. Also, as per the article published in Nature Reviews Drug Discovery in July 2020, several radiopharmaceutical therapy (RPT) agents are currently on the market, with many more in development. For instance, Bayer is developing Radium-223 chloride for Bone metastasis, Novartis is developing 177Lu-labelled DOTATATE for Neuroendocrine tumors, and Telix Pharma developing 211At-labelled aLAT-1a for Multiple myeloma. These include four B-particle and five α-particle emitters. Lead-212 decays to bismuth-212 and is used to deliver 212Bi, an α-emitter, without being constrained by its 1-hour half-life. Of the 30 RPT agents mentioned in the article, 13 deliver radionuclides that decay by α-particle emission. The interest in α-emitters reflects a potential growth area in RPT. The development of the RPT is increasing as the incidence and demand for treatment are rising, leading to the oncology segment growth in the market.

Geographical Analysis

North America region holds the largest market share of the global radiopharmaceuticals market

North America dominates the radiopharmaceutical market and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to rising cancer and another disease, advanced healthcare, launching new products and the presence of many key players. In July 2022, according to the Centers for Disease Control and Prevention, About 20.1 million adults age 20 and older have CAD (about 7.2%). With the rising incidence of disease, there is a demand for suitable treatment in the North American region.

In addition, the key players are adopting market strategies to expand their business. For instance, in November 2020, Canadian radiopharmaceuticals leading company Fusion Pharmaceuticals collaborated with Anglo-Swedish Pharma leader AstraZeneca to commercialize and develop next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Also, in July 2022, PETNET Solutions Inc., a Siemens Healthineers company and the leading manufacturer of radiopharmaceuticals for positron emission tomography (PET) imaging in the United States, opened a new radiopharmacy in Florida, United States.

Competitive Landscape

The radiopharmaceuticals market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Siemens AG, Positron Corporation, Curium, GE Healthcare, Lantheus Holdings Inc., Sotera Health LLC, Bayer AG, Eckert & Ziegler, Novartis AG, and BWX Technologies Inc. among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, which are contributing to the growth of the radiopharmaceutical market globally.

For instance,

  • In March 2021, Aktis Oncology, a biotechnology company developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancer cases, announced the completion of a series for solid tumors.

Novartis AG

Overview:

Novartis AG is a Swiss-American multinational pharmaceutical company founded in 1996 and headquartered in Switzerland. The company offers radiopharmaceutical products, including gallium Ga 68, for treating diseases such as cancer, cardiology, neurology and infectious & inflammatory diseases.

Product Portfolio:

PLUVICTO: The PLUVICTO brand name for lutetium Lu 177 vipivotide tetraxetan is used for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who has been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

The global radiopharmaceuticals market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. High prevalence of cancer and cardiovascular disease
      • 4.1.1.2. Rising demand for infection control measure
    • 4.1.2. Restraints:
      • 4.1.2.1. The short half-life of radiopharmaceuticals
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Radioisotopes

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes Segment
    • 7.1.2. Market Attractiveness Index, By Radioisotopes Segment
  • 7.2. Tec.99 *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. F18
  • 7.4. Iodine 131
  • 7.5. Lutetium 177
  • 7.6. Yttrium 90
  • 7.7. Gallium 68
  • 7.8. Gallium 67
  • 7.9. Rubidium 82
  • 7.10. Iodine 123
  • 7.11. Iodine 125
  • 7.12. Indium 111
  • 7.13. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Oncology *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Cardiology
  • 8.4. Gastroenterology
  • 8.5. Neuroendocrinology
  • 8.6. Neurology
  • 8.7. Nephrology
  • 8.8. Others

9. By Source

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 9.1.2. Market Attractiveness Index, By Source
  • 9.2. Cyclotrons *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Nuclear Reactor

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 10.1.2. Market Attractiveness Index, By End User Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Diagnostic Imaging Centers
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Cancer Research Institute

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Treatment type Benchmarking

13. Company Profiles

  • 13.1. Siemens AG*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Positron Corporation
  • 13.3. Curium
  • 13.4. GE Healthcare
  • 13.5. Lantheus Holdings Inc.
  • 13.6. Sotera Health LLC
  • 13.7. Bayer AG
  • 13.8. Eckert & Ziegler
  • 13.9. Novartis AG
  • 13.10. BWX Technologies Inc.

LIST NOT EXHAUSTIVE

14. Global Radiopharmaceuticals market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us